04:56 PM EDT, 10/14/2025 (MT Newswires) -- EyePoint Pharmaceuticals ( EYPT ) said Tuesday it is initiating its phase 3 program to evaluate Duravyu for the treatment of diabetic macular edema.

First patient dosing is expected in Q1 2026, the company said.

EyePoint said the phase 3 program will comprise two identical non-inferiority trials, with each trial to enroll about 240 people.

The company also said new preclinical data showed that vorolanib, the active drug in Duravyu, blocks both vascular endothelial growth factor-mediated vascular permeability and IL-6-mediated inflammation, which are key contributors to wet age-related macular degeneration and diabetic macular edema.

Shares of EyePoint Pharmaceuticals ( EYPT ) were down 2.4% in after-hours trading.